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The a2/a3GABAA receptor modulator TPA023B
alleviates not only the sensory but also the tonic
affective component of chronic pain in mice
Elena Neumanna, Laura Küpfera, Hanns Ulrich Zeilhofera,b,c,*
Abstract
Diminished synaptic inhibition in the spinal dorsal horn is a major contributor to pathological pain syndromes of neuropathic or
inflammatory origin. Drugs that enhance the activity of dorsal horn a2/a3GABAARs normalize exaggerated nociceptive responses in
rodents with neuropathic nerve lesions or peripheral inflammation but lackmost of the typical side effects of less specific GABAergic
drugs. It is however still unknownwhether such drugs also reduce the clinically more relevant conscious perception of pain. Here, we
investigated the effects of the a2/a3GABAAR subtype-selective modulator TPA023B on the tonic aversive component of pain in
micewith peripheral inflammation or neuropathy. In neuropathicmicewith a chronic constriction injury of the sciatic nerve, TPA023B
not only reversed hyperalgesia to tactile and heat stimuli but also was highly effective in the conditioned place preference test. In the
formalin test, TPA023B not only reduced licking of the injected paw but also reversed facial pain expression scores in the mouse
grimace scale assay. Taken together, our results demonstrate that a2/a3GABAA receptor subtype-selective modulators not only
reduce nociceptive withdrawal responses but also alleviate the tonic aversive components of chronic pain.
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Conditioned place preference, Paclitaxel, Chronic constriction injury, Mouse grimace scale
1. Introduction
Diminished GABAergic inhibition in the spinal dorsal horn is a
major contributor to different chronic pain forms.16,40,47 Facilita-
tion of GABAergic inhibition in the spinal cord through benzodi-
azepine (BDZ) site ligands, which positively modulate GABAA
receptor (GABAAR) function, reverses pathologically increased
pain sensitivity (hyperalgesia) in rodent models of chronic
inflammatory and neuropathic pain.13 Work in genetically
modified (point-mutated “knock-in”) mice, in which only 1
GABAAR subtype was left BDZ-sensitive, has demonstrated that
targeting a2GABAAR and a3GABAAR provides effective anti-
hyperalgesia in the absence of typical BDZ-mediated side
effects.34 This is in line with previous studies that showed that
most undesired effects of classical BDZ agonists, such as
sedation, impaired motor coordination, tolerance development,
and addiction, can be avoided by sparing modulation of
a1GABAARs.
34,38,42 These findings have prompted the de-
velopment of BDZ site ligands with improved subtype selectivity.
Several such compounds (L-838,417, HZ-166, SL-651498, and
NS11394) have been proven to be efficacious in different
preclinical pain models. However, these models used almost
exclusively classical withdrawal readout-based pain
tests5,13,14,19,24,31,36 or flexor responses in models using
chemically induced nociception.13,14,25 Such readouts might
not properly reflect the multidimensional experience of pain in
patients with its complex interplay of sensory, affective, and
cognitive components.2,8 Monitoring these affective aspects of
pain in nonverbal animals presents a major challenge. Recently,
operant learning paradigms, such as conditioned place prefer-
ence, and coding of facial expressions of pain have been used to
assess affective aspects of pain also in rodents.10,12,17,33,41
In this study, we investigated the effects of TPA023B, an a1-
sparing GABAAR modulator
44 developed by Merck in the quest
for nonsedative anxiolytics.1,15,39 We assessed effects of
TPA023B on the affective and the sensory components of pain
in different mouse pain models. Relative to several other a2/
a3GABAAR modulators, TPA023B has more favorable pharma-
cokinetics, and, as shown in a previous study on its antipruritic
actions, it is devoid of typical benzodiazepine drug-mediated side
effects, including sedation, muscle relaxation, impaired motor
coordination, and tolerance development.35 Furthermore,
TPA023B is well tolerated not only in rodents but also in dogs,
nonhuman primates, and humans.1,35,44 Here, we have
assessed its effects on evoked nocifensive responses in naive
mice and in mice with neuropathic or inflammatory insults and on
the affective component of on-going pain in 2 models of
mechanical and chemical nerve injury. We show that TPA023B
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not only reverses mechanical sensitization in mice with neuro-
pathic pain but also reduces the tonic the aversive component of
pain measured in the conditioned place preference test and the
mouse grimace scale (MGS) assay. These results indicate that
a2/a3GABAARmodulators are not only antihyperalgesic but also
effective against the affective component of chronic pain.
2. Methods
2.1. Animals and animal maintenance
All experiments were performed in 6- to 9-week-old female and
male mice at equal numbers, except the use of only male mice in
the paclitaxel-induced neuropathic pain model as described by
Braz et al.4Care was taken to ensure that animals were randomly
assigned to each group. Animals were bred in-house, group-
housed, and kept on 12/12 light/dark cycle (lights on at 07.00 AM;
Zeitgeber time (ZT) 5 0; light intensity 50 lux at 1 m above floor)
and were provided with food and water at all times. Experiments
were performed in wild-type C57BL/6J mice (colony established
with breeding pairs obtained from Janvier), in GABAAR point-
mutated mice, in which a2GABAARs had been rendered
benzodiazepine-insensitive (a2R/R; Ref. 18), in mice that lack
a2GABAARs specifically from the spinal cord (hoxB8-a2
2/2;
Refs. 31, 45) and in corresponding control littermates (a2fl/fl).
a2R/R mice, which carry a homozygous histidine to arginine (H-.
R) point mutation at position 101 of the gabra2 gene, have been
described previously by Löw et al.18 hoxB8-a22/2 mice were
bread as described previously.31,45 All mice were of the C57BL/
6J genetic background. Behavioral experiments were conducted
by the same female, experienced experimenter, blinded to the
genotype of the mice or their treatment with drug or vehicle. All
behavioral experiments were performed between 10.00 AM (ZT5
03) and 04.00 PM (ZT 5 09). Experimental rooms had a constant
temperature (20-21˚C), were without daylight, and were illumi-
nated with white light of 50 lux (measured 1 m above the floor). In
all tests, mice were allowed to acclimatize to the test apparatus
for at least 60 minutes, except for the conditioned place
preference test (see below). All procedures were performed in
accordance with the Veterinary Office of the Canton of Zürich
(licence numbers ZH135/2009, ZH063/2016, and ZH231/2017).
2.2. Drugs and drug administration
TPA023B (6,29-difluoro-5’-[3-(1-hydroxy-1methylethyl)imidazo
[1,2-b][1,2,4]triazin-7-yl]biphenyl-2-carbonitrile) was synthesized
by ANAWA (Wangen, Switzerland), and purity was.95%. For per
oral (p.o.) administration, TPA023B was suspended in 0.9%
saline (sodium chloride, Sigma-Aldrich) and 1% Tween80
(Sigma-Aldrich, St. Louis,MO). For intrathecal (i.t.) administration,
TPA023B was suspended in artificial cerebrospinal fluid (ACSF)
containing (in mM) 120 NaCl, 5 HEPES, 26 NaHCO3, 1.25
NaH2PO4, 2.5 KCl, 2 CaCl2, 1 MgCl2, and 10 glucose (pH 7.35)
(all from Sigma-Aldrich). The 4% formalin solution (pH 7.4) was
prepared from paraformaldehyde powder dissolved in 0.1-M
phosphate buffer containing NaH2PO4 and Na2HPO4 (all from
Sigma-Aldrich). For the p.o. administration of vehicle or drug, a
metal (stainless steel) gavage needle (20 G) was used (Thermo
Fisher Scientific, Waltham, MA). Mice were not trained for this
procedure. To ensure a successful and safe oral gavage
performance, the distance from the snout to the caudal point of
the sternum (xiphoid process) was measured with the metal
needle on the outside of the restrained animal and marked on the
needle with a permanent marker. Intrathecal injections were
performed under isoflurane (1.5%) anesthesia. A 30-G 0.5
stainless steel needle (Thermo Fisher Scientific) attached to a
25-mL Hamilton syringe was inserted between the groove of L5
and L6 vertebrae. A tail flick indicated a successful insertion of the
needle in the intradural space.
2.3. Chronic constriction injury–induced neuropathic
pain model
To induce neuropathic pain, chronic constriction injury (CCI) was
applied to the left sciatic nerve proximal to the trifurcation with 3
loose (5-0, not absorbable) silk (Ethicon, Somerville, NJ) ligatures
in mice anesthetized with isoflurane 1% to 3%.3 Skin was closed
using 5-0 Dermalon suture (Covidien, Minneapolis, MN).
2.4. Paclitaxel-induced neuropathic pain model
We used the paclitaxel model to produce mechanical and heat
hypersensitivity thatmimicschemotherapy-inducedneuropathic pain
conditions. In brief, we injected male mice with 250 mL of 1-mg/kg
paclitaxel (Sigma-Aldrich), dissolved in 40% DMSO (Sigma-Aldrich),
intraperitoneally (i.p.) 4 times, every other day at 10 AM (ZT5 03).4
2.5. Formalin test
To chemically induce inflammatory pain, 10 mL of a 4% formalin
solution was injected subcutaneously into the left hind paw
without anesthesia using a custom-made mouse restrainer. The
time spent licking the left hind paw and the facial expression of the
mice (MGS, Ref. 17) were evaluated 15 to 60 minutes after
injection.
2.6. Assessment of mechanical and thermal sensitivity
Mechanical sensitivity was quantified as the change in the paw
withdrawal threshold evoked by an electronic von Frey filament
(IITC Inc Life Science, Woodland Hills, CA). Heat sensitivity was
determined by the measurement of paw withdrawal latency to a
defined radiant heat stimulus applied to the plantar surface of the
left hind paw. These experiments were performed using the
Plantar Analgesia Meter (IITC Inc Life Science). Heat intensity was
set to 14, the plate was prewarmed to 37˚C, and the cutoff time
was set to 32 seconds to avoid tissue damage.
2.7. Conditioned place preference
Theconditionedplacepreferenceapparatusconsistedof 2chambers
(20 3 20 cm), which were identical in size but could be visually
distinguished by their different wall patterns (uniform black vs 3-cm
broad black and white horizontal stripes). The chambers were
connected through a tunnel (3.8310.0313.7 cm [W3L3H]), the
entrances of which were blocked during the conditioning sessions.
Mice were recorded with an HD digital video camera, and the time
spent in each chamber was analysed manually. Preconditioning
started7daysafterCCI surgery.Micehad free access toall chambers
for 30 minutes on days 7 and 8 after CCI surgery. On day 9, a
preconditioning bias test was performed and the time spent in the 2
chambers was measured for 20 minutes. Mice spending more than
80%, or less than 20% of the total time in 1 chamber, were excluded
from the experiment (0, 3, 5, 2, and 0, from the experiments shown in
Figs. 1–5, respectively). On the conditioning day (day 10), mice were
i.t. injectedwith vehicle (ACSF, total volume of 5mL) and paired for 45
minutes with a randomly chosen chamber in the morning. Access to
the other chamber and tunnel was blocked. Four hours later, mice
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Figure 1. Effects of TPA023B in stimulus-evoked CCI-induced neuropathic and acute nociceptive pain. (A) Reversal of chronic constriction injury (CCI)-induced
mechanical hyperalgesia by TPA023B in wild-type (C57BL/6J) mice assessed with von Frey filaments (mean6 SEM, n5 6, 6, and 7 mice, for vehicle, 0.3 mg/kg,
and 1 mg/kg TPA023B p.o., respectively). The maximum possible antihyperalgesia (MPE) was calculated from the drug effects during 60 to 180 minutes after
TPA023B administration. Statistics, time course of changes in pawwithdrawal latencies (left panel): repeated-measures ANOVA followed by the Dunnett post hoc
test with predrug baseline (time5 0) as reference. Vehicle: F(5,30)5 0.5; P5 0.87, 0.43, 0.81, 0.30, 1.0, and 1.0 for time 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 hours,
respectively. TPA023B (0.3mg/kg): F(5,30)5 2,48;P5 0.20, 0.06, 0.0009, 0.043, 0.03, and 0.005, for 0.5, 1.0, 1.5, 2, 2.5, and 3.0 hours, respectively; TPA023B
(1 mg/kg): F(6,36) 5 4.04; P 5 0.0001, 0.02, 0.0007, 0.01, 0.01, and 0.005, for 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 hours, respectively. MPE (right panel): one-way
ANOVA followed by the Dunnett post hoc test F(2,16) 5 87.9. (B) Same as (A) but heat hyperalgesia (n 5 7, 6, and 7 mice, for vehicle, 0.3 mg/kg, and 1 mg/kg
TPA023B p.o., respectively). Time course (left panel): F(6,36)5 29.18. P5 1.0, 0.50, 0.39, 1.0, 1.0, and 0.06, for 0.5, 1.0, 1.5, 2.0, 2.5, and 3 hours, respectively;
TPA023B (0.3 mg/kg): F(5,30) 5 23.3. P 5 0.99, 0.04, 0.31, 0.014, 0.03, and 0.01, for 0.5, 1.0, 1.5, 2.0, 2.5, and 3 hours, respectively; TPA023B (1 mg/kg):
F(6,36)5 16.3. P5 1.0, 0.14, 0.008, 0.004, 0.003, and 0.002, for 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 hours, respectively. MPE (right panel): F(2,17)5 42.9. (C) Effects
against acute nociceptive pain in naive C57BL/6J mice. TPA023B (1 mg/kg p.o.) did not alter responses to acute noxious heat (Hargreaves) and cold (dry ice)
stimuli nor to light mechanical stimulation with von Frey filaments or a paintbrush (mean6 SEM, n5 7). One-way ANOVA followed by the Bonferroni post hoc test,
F(3,24) 5 0.9 for the Hargreaves test; F(3,24) 5 0.3 for the cold test; F(3,24) 5 0.7 for the von Frey test; F(3,24) 5 0.2 for the brush test. ANOVA, analysis of
variance.
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were i.t. injected with TPA023B (0.3 mg/kg in 5 mL) and paired with
the other chamber. Chamber pairings were counterbalanced. On the
next day (day 10 after CCI surgery), 20 hours after administration of
TPA023B and after the afternoon pairing, mice were placed in the
tunnel of the conditioned place preference apparatus with access to
both chambers and recorded for 20 minutes for analysis of chamber
preference. The person analysing the videos was blinded to the
genotype and treatment of the animals. The conditioned place
preference apparatus was cleanedwith water before the next mouse
was placed into the apparatus.
2.8. Mouse grimace scale
Weused theMGSasa standardizedbehavioural coding system for
facial pain expressions as described by Langford et al.17 In brief,
mice were placed individually in transparent plexiglass cubicles (15
3 153 15 cm; L3W3H) for acclimatization. Next, vehicle (0.9%
saline and 1% Tween80) or drug (1-mg/kg TPA023B in 250-mL
vehicle) was administered orally, and the animals were put back
into their cage.One hour later, formalin was injected andmicewere
placed in cubicles and recorded for 45 minutes with 2 HD digital
video cameras positioned on opposite sides. For every condition, 6
images of the face were taken as screenshots from the obtained
recordings. A screenshot was extracted on every occasion as long
as the face was clearly visible and the mouse was not grooming or
sniffing. For analysis, randomly arranged sets of mouse photo-
graphs were scored by 2 persons (“coders”) blinded to the
treatment status of the mice. These coders assigned a value of
0 (not present), 1 (moderately visible), or 2 (severe) for 4 facial
features (orbital tightening, nose bulge, cheek bulge, and ear
position). When the coder was unsure whether themouse showed
amoderately visible facial expression or not, a score of 1 was given
as described in Matsumiya et al.21 The final MGS score was the
average across all criteria of every coder.
2.9. Statistics
Data are expressed as mean 6 SEM. Where appropriate, data
were analysed using a 1-way or 2-way repeated-measures
analysis of variance (ANOVA) and subsequent pairwise
Figure 2. TPA023B reduced the tonic aversive component of on-going pain in the CCI mice. (A) Design and timeline of the conditioned place preference (CPP)
experiment. (B) TPA023B (0.3 mg/kg, i.t.) normalized mechanical paw withdrawal thresholds measured on the conditioning day immediately after mice with CCI-
induced neuropathy had undergone drug conditioning. Repeated-measures ANOVA followedby the Dunnett post hoc testwith pawwithdrawal thresholds at predrug
baseline (time50) as reference.Naivemice (n512): F(11,55)50.93.P51.0, 0.43, 0.95, 0.62, and 0.97, for 1.0, 1.5, 2.0, 3.0, and4.0 hours, respectively. CCImice (n
59): F(8,40)51.4.P, 0.0001 for 1.0, 1.5, and 2.0 hours,P5 0.0002 for 3 hours, andP50.98 for 4.0 hours. (C) Time (mean6SEM) spent in vehicle- and TPA023B-
paired chambers for naive wild-type (C57BL/6J) mice (n5 12) and wild-type (C57BL/6J) mice that had undergone CCI surgery (n5 9), before and after conditioning.
After 2 acclimatization sessions ondays7 and 8, the time spent in the 2 chamberswasmeasuredduring a 20-minute preconditioning session to ensure the absenceof
chamber bias. (A) significant chamber x preconditioning/postconditioning interaction was obtained for CCI-operatedmice but not for naivemice. Two-way repeated-
measures ANOVA: naive mice F(1,11)5 0.48; CCI mice F(1,8)5 18.6; Subsequent pairwise comparisons demonstrated a preference for the drug-paired chamber
only for CCI mice after conditioning. ANOVA, analysis of variance; CCI, chronic constriction injury.
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comparisons. Maximum possible analgesic effects were
analysed using 1-way ANOVA followed by the Dunnett post
hoc tests. Formalin assay data and paclitaxel-induced neu-
ropathy data were analysed using the unpaired t test. In
all statistical analyses, results were considered significant when
P , 0.05.
2.10 Data availability.
Excel files including the data that support the findings of this study
are available at G-Node.org with the identifier doi: 10.12751/g-
node.ogsof3 [https://doi.gin.g-node.org/10.12751/g-node.ogsof3].
3. Results
3.1. Effects of TPA023B on noxious stimulus-evoked
responses in naive and neuropathic mice
TPA023B is one of the most selective nonsedative (a1GABAAR-
sparing) benzodiazepine site agonists currently available.1,44
Although previous work with other a1GABAAR-sparing com-
pounds suggests that it should possess antihyperalgesic
efficacy, such actions have not yet been directly demonstrated.
We therefore first verified the presence of such antihyperalgesic
actions of TPA023B in the CCI model of neuropathic pain. After
surgery, all 39 operated mice developed pronounced mechan-
ical and heat hyperalgesia. Seven days after surgery, mice
Figure 3. Conditioned place preference in neuropathic mice lacking a2GABAARs specifically from the spinal cord. (A) Time (mean 6 SEM) spent in vehicle- and
TPA023B-paired chambers for a2fl/fl (n 5 7), hoxB8-a22/2 (n5 8) and a2R/R mice (n5 7) before and after conditioning. TPA023B (0.3 mg/kg, i.t.) produced place
preference in neuropathic a2fl/fl mice for the drug-paired chamber, whereas neuropathic hoxB8-a22/2 mice and a2R/R mice spent similar amounts of time in both
chambers. Two-way repeated-measures ANOVA yielded significant chamber x preconditioning/postconditioning interaction for a2fl/fl mice but not for hoxB8-a22/2
and a2R/R mice a2fl/fl (F(1,6) 5 10.9, P 5 0.016; hoxB8-a22/2: F(1,7) 5 0.274; P 5 0.617; a2R/R: F(1,6) 5 0.47; P 5 0.518). Pairwise comparisons showed a
preference for the TPA023B-pairedchamber ina2fl/flmiceafter conditioning, but not for any of theother pairs. (B) Partial reversal ofmechanical thresholds byTPA023B
(0.3 mg/kg, i.t.) measured immediately after neuropathic hoxB8-a22/2 and a2R/R mice underwent drug conditioning. TPA023B almost completely reversed
mechanical sensitization in neuropathica2fl/flmice (mean6SEM, n5 7 [a2fl/fl], 8 [hoxB8-a22/2], and 7 [a2R/R]). Time course (left panel). Repeated-measures ANOVA
followed by the Dunnett post hoc test with withdrawal thresholds at predrug baseline (time 5 0) as reference. a2fl/fl mice: F(6,30)5 3.67. P5 0.002, 0.003, 0.005,
0.015, and 0.15, for 1.0, 1.5, 2.0, 3.0 and 4.0 hours, respectively; hoxB8-a22/2mice: F(7,35)5 5.1.P5 0.003, 0.003, 0.001, 0.06 and 1.0, for 1.0, 1.5, 2.0, 3.0, and
4.0 hours, respectively; a2R/R mice: F(6,30) 5 2.28. P , 0.0001, P 5 0.0002, P , 0.0001, P 5 0.01 and 0.26, for 1.0, 1.5, 2.0, 3.0, and 4.0 hours, respectively.
Maximum possible antihyperalgesia (MPE; right panel) was determined from paw withdrawal latencies obtained at 60 to 120 minutes after TPA023B administration.
One-way ANOVA followed by the Dunnett post hoc test F(2,20) 5 5.9. ANOVA, analysis of variance.
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were treated systemically with 2 different doses of TPA023B
(0.3 or 1 mg/kg p.o.) or with vehicle. The doses were chosen
based on a previous study with well-established dose–response
curves.35 TPA023B exerted a dose-dependent antihyperalgesic
action expressed as percent maximum possible effect (mechan-
ical hyperalgesia: 30.4 6 3.9% and 67.2 6 4.0%, for 0.3 mg/kg
and 1 mg/kg TPA023B, respectively; heat hyperalgesia: 65.1 6
7.7% and 122.26 12.2%, for 0.3 mg/kg and 1 mg/kg TPA023B,
Figure 4. TPA023B reduced mechanical hyperalgesia but not the aversive component of tonic pain in mice with paclitaxel-induced neuropathy. (A) Timeline of
paclitaxel injections and stimulus-evoked behavior tests. (B) TPA023B (1 mg/kg p.o.) reversed paclitaxel-induced mechanical hyperalgesia (2-way repeated-
measures ANOVA revealed a significant time3 drug interaction F(1,23)5 18.1,P, 0.001; n5 12 and 13, for vehicle- and TPA023B-treated groups). Subsequent
pairwise comparisons yield a significant difference for baseline vs TPA023B (P , 0.0005). (C) TPA023B (1 mg/kg p.o.) did not alter heat thresholds in the
Hargreaves test (2-way repeated-measures ANOVA time x drug interaction F(1,23)5 0.37,P5 0.55). Samemice as (B). (D) Conditioned place preference protocol
in mice with paclitaxel-induced neuropathy. Two-way repeated-measures ANOVA did not yield a significant chamber x preconditioning/postconditioning
interaction. F(1,11) 5 0.32; P 5 0.56. (E) TPA023B (0.3 mg/kg, i.t.) reduced mechanical sensitization, measured immediately after mice underwent drug
conditioning. Repeated-measures ANOVA followed by the Dunnett post hoc test showed significant recovery from paclitaxel-inducedmechanical hypersensitivity
by TPA023B for all time points (F(11,55)5 3.22; P5 0.0003, 0.0009, P, 0.0001, P5 0.04 after 1.0, 1.5, 2.0, and 3.0 hours, respectively) except for 4 hours (P5
0.99). No such effect was observed in naive mice: F(3,15)5 0.94.P5 1.0 after 1.0, 1.5, and 2.0 hours, respectively,P5 0.75 after 3 hours,P5 0.87 after 4 hours.
(F) TPA023B did not produce conditioned place preference for the TPA023B-paired (475 6 33 seconds) chamber compared with the vehicle-paired (506 6 30
seconds) chamber in paclitaxel-injectedmice. Two-way repeated-measures ANOVA F(1,44)5 0.5, followed by pairwise comparisons, n5 12. ANOVA, analysis of
variance.
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respectively; Figs. 1A and B). Separate experiments revealed
that significant antihyperalgesia by 1 mg/kg p.o. TPA023B lasts
for at least 6 to less than 10 hours (Neumann et al., unpublished).
In previous experiments, in which we had used the nonselective
prototypical benzodiazepine site agonist diazepam in GABAAR
point-mutated mice, we have found that facilitation of GABAergic
inhibition failed to reduce sensitivity to acute nociceptive stimuli in
naive (nonsensitized) mice.35 We therefore tested next whether
TPA023B would show a similar lack of acute antinociceptive
activity (Fig. 1C). Indeed, TPA023B (1 mg/kg p.o.) did not alter
response thresholds or latencies upon exposure of naive mice to
acute noxious heat (Hargreaves test) or noxious cold exposure
(cold plantar test). Furthermore, it did not change responses
to light mechanical stimulation with von Frey filaments or a
paintbrush.
3.2. TPA023B reduced the tonic aversive component of on-
going pain in neuropathic mice
We next investigated whether the action of TPA023B would be
limited to evoked nociceptive responses in sensitized mice or
whether it would also reduce the aversive component of tonic
pain. To this end, we used the conditioned place preference test
(Fig. 2A) in CCI mice and applied TPA023B i.t. at a dose of 0.3
mg/kg. The i.t. administration route was chosen for 2 reasons: (1)
The faster onset of pain relief (as compared to oral administration)
should facilitate the association of drug action with the drug-
paired chamber, and (2) potential confounding reward-related or
anxiolytic properties, which would originate from supraspinal
sites, should be less likely to occur.
On day 7 after CCI surgery, before conditioned place
preference conditioning, the presence of mechanical sensitiza-
tion was confirmed. Animals had paw withdrawal thresholds of
1.57 6 0.07 g after CCI surgery compared with 4.11 6 0.05 g
before surgery. On days 7, 8, and 9, the preconditioning was
performed. Mice were placed into the conditioned place
preference apparatus with free access to both chambers. Mice
that spent less than 20% or more than 80% in 1 chamber were
excluded. On the conditioning day (day 10 after surgery), mice
received first a vehicle injection and were then transferred
immediately after injection into 1 chamber for 45 minutes without
access to the other compartments of the conditioned place
preference apparatus (“chamber pairing”). Four hours later, the
same mice were injected with TPA023B (0.3 mg/kg, i.t.) and
placed into the other chamber for 45 minutes. To verify the
presence of an analgesic effect in each of the mice, mechanical
pain thresholds were tested with von Frey filaments, immediately
after this conditioning. Comparedwith the values obtained on day
7 (predrug baseline), mice exhibited reduced sensitization (ie,
increased pawwithdrawal thresholds: 3.496 0.15 g after 1 hour;
3.76 0.13 g after 1.5 hours; 3.376 0.14 g after 2 hours; and 2.46
6 0.11 g after 3 hours). Within 4 hours after injection, response
thresholds returned to pretreatment baseline values (1.636 0.09
g) (Fig. 2B). On the next day, animals were placed without further
drug treatment into the tunnel connecting the 2 chambers of the
conditioned place preference apparatus with free access to both
chambers. Mice with CCI-induced hyperalgesia showed a
pronounced preference for the drug-paired chamber (549 6 37
seconds) compared with the vehicle-paired chamber (346 6 23
seconds) (Fig. 2C). Naive mice that had not undergone CCI
surgery but the same conditioning procedure spent similar
amounts of time in the vehicle (450 6 18 seconds) and drug-
paired (466 6 20 seconds) chambers, indicating that i.t.
administration of TPA023B did not induce place preference in
the absence of a tonic pain condition. Naive mice were used as
controls instead of sham-operated animals because any post-
surgical pain remaining in sham-operated mice might have
caused conditioned place preference and would have made it
impossible to exclude pain-independent rewarding properties of
the test drug.
3.3. Conditioned place preference by TPA023B in
neuropathic mice exclusively depends on a2GABAA
receptors located in the spinal cord
Although TPA023B had been i.t. injected in the conditioned place
preference experiments described above, we cannot fully
exclude that it reached supraspinal sites through rostral diffusion
within the cerebrospinal fluid or after absorption into the systemic
circulation. To exclude potential effects arising from supraspinal
GABAARs, we took a genetic approach and made use of hoxB8-
a22/2 mice that lack a2GABAARs specifically from the spinal
cord31 (Fig. 3A). We compared the effects of TPA023B in the
conditioned place preference test in hoxB8-a22/2 mice with
those in global a2GABAAR point-mutated mice (a2
R/R), in which
all a2GABAARs have been rendered insensitive to diazepam
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Figure 5. TPA023B alleviated chemically induced inflammatory pain. TPA023B (1 mg/kg p.o.) reduced the time spent licking the injected paw and reversed facial
pain expressions in C57BL/6 mice with formalin-induced pain (mean 6 SEM, n 5 6, unpaired t test).
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and at the same time also to several other benzodiazepine site
agonists including TPA023B.31,35 a2fl/fl mice were used as wild-
type controls. Nine days after CCI surgery, none of the 3 mouse
lines showed a pre-existing chamber bias in the conditioned
place preference test. After conditioning, a2fl/fl mice showed the
expected preference for the TPA023B-paired chamber, similar to
what we have previously observed with wild-type C57BL/6 mice.
This conditioned place preference was absent in hoxB8-a22/2
mice (and global a2R/R point-mutated mice), indicating that
supraspinal a2GABAARs did not contribute to the conditioned
place preference effect. hoxB8-a22/2 mice spent 4996 53 and
472 6 55 seconds in the vehicle-paired and drug-paired
chamber, respectively, and a2R/R point-mutated mice spent
494 6 46 and 518 6 47 seconds in the 2 chambers. The same
mice were also tested in the von Frey test (Fig. 3B). No significant
differences were observed between hoxB8-a22/2 mice (41.1 6
5.9% maximum possible drug effect) and global a2R/R mice
(40.9 6 2.6% maximum possible drug effect), again excluding a
contribution of supraspinal a2GABAARs. However, although the
preference for the drug-paired chamber was completely lost in
both, hoxB8-a22/2 mice and in global a2R/R mice, both of these
mouse lines showed only a partial reduction in TPA023B-induced
antihyperalgesia (relative to a2fl/fl mice), suggesting that
GABAARs contribute differently to the control of the sensory
and the aversive components of pain.
3.4. TPA023B effects in mice with paclitaxel-
induced neuropathy
We next assessed the antihyperalgesic potential of TPA023B in a
second neuropathic pain model. To this end, we chose chronic
treatment with the anticancer drug paclitaxel as a model of
chemotherapy-induced neuropathic pain. Paclitaxel (1 mg/kg,
i.p.) was injected 4 times, every other day (Fig. 4A), and led to the
development of mechanical and heat hyperalgesia (von Frey test,
P , 0.0001 and Hargreaves test, P , 0.0001, paired t test, n 5
25 mice). TPA023B (1 mg/kg p.o.) significantly reduced
paclitaxel-induced mechanical sensitization but had no effect
on heat hyperalgesia in this model (Figs. 4B and C). We then
investigated the actions of TPA023B on conditioned place
preference in mice with paclitaxel-induced mechanical hyper-
algesia using the same conditioning protocol as used previously
for the CCI mice (Fig. 4D). Paclitaxel reduced the thresholds of
paw withdrawal responses upon stimulation with von Frey
filaments from 4.08 6 0.02 g before paclitaxel treatment to
2.33 6 0.12 g after paclitaxel (n 5 12) (Fig. 4E). On the
conditioning day, mice received first vehicle i.t. treatment and
were paired with 1 chamber. Four hours later, mice were treated
with TPA023B (0.3 mg/kg, i.t.) paired with the other chamber.
After drug conditioning was completed, paw withdrawal thresh-
olds were again assessed with von Frey filaments. To permit
blinding of the experimenter, 4 naive animals were included in the
von Frey tests. Although TPA023B (0.3 mg/kg, i.t.) was
efficacious against paclitaxel-induced mechanical hyperalgesia
(3.386 0.14 g after 1 hour, 3.336 0.17 g after 1.5 hours, and 3.3
6 0.14 g after 2 hours, Fig. 4E), it did not induce a place
preference (506 6 30 seconds for the vehicle-paired chamber
and 475 6 33 seconds for TPA023B-paired chamber, Fig. 4F).
3.5. TPA023B reverses facial expressions of pain in the
formalin test
Finally, we assessed the analgesic actions of TPA023B on
formalin-induced spontaneous pain using the MGS assay,17
which is a standardized facial coding system well-suited for
rodent pain models of moderate duration. Systemic treatment
with TPA023B (1 mg/kg p.o.) not only significantly reduced the
time spent licking the injected paw (4016 42 seconds and 576
28 seconds, for vehicle- and TPA023B-treated mice, respec-
tively, n5 6) but also reversed facial pain grimacing (1.316 0.04
MGS score and 0.26 6 0.06 MGS score for vehicle- and
TPA023B-treated mice, respectively, n 5 6) caused by sub-
cutaneous formalin injections compared with vehicle-treated
mice (Fig. 5).
4. Discussion
A large body of evidence indicates that an enhancement of the
inhibitory actions of spinal a2/a3GABAARs alleviates inflamma-
tory and neuropathic hyperalgesia in mice.5,13,14,19,24,31,34
Attempts to translate these preclinical concepts into patient
therapy have not yet been successful. In fact, a clinical trial testing
PF-06372865, an a2/a3-selective GABAAR modulator devel-
oped by Pfizer, in patients with chronic low back pain has failed.9
Possible reasons of this discrepancy include differences between
readouts typically used in mouse pain models and in clinical trials.
Preclinical testing in rodents largely relies on nocifensive
withdrawal responses that measure response thresholds upon
exposure to an acute nociceptive stimulus and hence address
primarily the sensory component of pain. By contrast, the
impairment of patients with chronic pain results mainly from on-
going suprathreshold pain and includes a strong affective
component.2,8 Clinical trials on analgesic drugs therefore focus
primarily on subjective self-reported pain. Relatively recently
developed novel preclinical assays permit a stimulus-
independent evaluation of the affective component of on-going
and suprathreshold pain also in rodents.10,12,17,41 In this study,
we have used 2 of these assays, namely conditioned place
preference in a model of neuropathic pain and the MGS in the
formalin test. In both of these assays, we obtained compelling
evidence for a beneficial effect of TPA023B on the affective
component of tonic pain. We should add here that our
experiments on mice exposed to CCI surgery included naive
mice as controls but no sham-operated mice. For this reason, the
analgesic action observedmay include analgesia directed against
postoperative pain. However, a previous study12 found no
conditioned place preference with other analgesic drugs (cloni-
dine and lidocaine) in sham-operated mice.
Activation of the brain reward system and anxiolytic drug
actions are well-known confounding factors in conditioned place
preference paradigms.43 Rewarding and anxiolytic actions are
also known to occur with classical nonselective benzodiazepine
site agonists. An activation of the brain reward system in our
experiments with TPA023B as an underlying cause of its effects in
the conditioned place preference experiments is unlikely because
TPA023B did not induce any place preference in naive (pain-free)
mice. Furthermore, previous work has demonstrated that a1-
sparing benzodiazepine site ligands lack rewarding proper-
ties.7,37,42 In this context, it should be noted that relief of pain
or, in general, of aversive states activates the brain reward
pathway.27 Such analgesia-induced activation of brain reward
circuits likely contributes to the conditioned place preference
observed with analgesic treatments. Ruling out a potential
anxiolytic action as a confounding factor is more complex,
especially since a2GABAARmodulators, including TPA023B, are
anxiolytic18,28 and because animals with neuropathic pain exhibit
elevated levels of anxiety.22,26 To exclude false-positive effects
from an anxiolytic drug action, we verified that the action of
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TPA023B in the conditioned place preference paradigm
depended exclusively on spinal a2GABAARs and did not involve
supraspinal receptors.
Our conditioned place preference experiments with i.t. injected
TPA023B have yielded another intriguing result. Specific ablation
of all a2GABAARs from the spinal cord completely prevented
TPA023B-induced conditioned place preference in CCI mice. By
contrast, the antihyperalgesic action of TPA023B measured in
the same mice was only partially reduced, suggesting that the
sensory and affective components of pain are differentially
sensitive to changes in GABAergic inhibition. Several previous
studies have already reported differential effects of adenosine on
sensory hyperalgesia and the affective pain component. In
particular, King et al.12 have shown that i.t. administration of
adenosine reversed spinal nerve ligation–induced tactile allodynia
but did not induce conditioned place preference. Martin et al.20
have demonstrated that i.t. adenosine reversed mechanical
hypersensitivity in rats with spared nerve injury–induced neurop-
athy but failed to reduce heroin self-administration in these
animals. These findings are in line with human data by Eisenach
et al.6 reporting that spinal adenosine blocked secondary
hyperalgesia, which was detected with evoked stimuli, in patients
with neuropathic pain but had no effect on their overall pain
ratings. Despite these examples, it is obvious that the sensory
and affective components of pain processing are interrelated
because, eg, a complete block of sensory detection would also
suppress affective responses.
In this study, we have used 2 different neuropathic pain
models, the CCI of the sciatic nerve and paclitaxel-induced
neuropathy. In both models, TPA023B was effective against
hyperalgesic withdrawal responses, but conditioned place
preference by TPA023B was only observed in CCI mice but not
in mice with paclitaxel-induced neuropathy. The reason for this
discrepancy is currently unknown. Tooweak on-going pain in this
model might explain the absence of a TPA023B effect in the
conditioned place preference model. However, other authors
have found effects of other analgesics on conditioned place
preference in the same paclitaxel model,11 putting this explana-
tion into perspective. Alternatively, one might speculate that the
impairment of GABAergic inhibition is more severe in CCI-
operated mice than in paclitaxel-treated mice, which would
render mice with paclitaxel-induced neuropathy less susceptible
to analgesia by GABAergic compounds. This explanation would
be also supported by the slightly weaker effect on evoked pain
responses of TPA023B in paclitaxel-treated mice relative to mice
with CCI-induced neuropathy (compare Figs. 2B and 4E). Gene
expression analyses have indeed found significant reductions in
the GABA-producing enzymes GAD-65 and GAD-67 after
peripheral mechanical nerve injury,23while no significant changes
were reported in a study that investigated spinal cord of mice with
paclitaxel-induced neuropathy.4 As GABAAR modulators likely
relieve pathological pain associated with a deficit in GABAergic
inhibition, this difference may explain why nerve injury–induced
hyperalgesia responds better to TPA023B than paclitaxel-
induced neuropathic pain.
Similar considerations might also explain the differential
efficacy of GABAAR modulators in models of inflammatory or
neuropathy-induced hyperalgesia vs acute nociception. Recent
work has shown that neuropathic sensitization involves the
functionalization of normally silent dorsal horn circuits that
connect Ab fiber input to lamina I projections neurons through
multiple interneurons.32,46 This polysynaptic relay becomes
functional in the course of diminished synaptic inhibition and
should hence be highly sensitive to drugs strengthening
GABAergic inhibition. By contrast, acute nociceptive responses
rely more on monosynaptic connections.19 Such monosynaptic
connections are also tuned by GABAergic inhibition but are less
likely to be completely silenced by enhancers of GABAergic
inhibition. In this context, it might be worth mentioning that
TPA023B is effective against acute itch35 and hence likely in the
absence of disinhibition. Interestingly, unlike acute nociceptive
transmission, the spinal relay of acute chemical itch signals
occurs through at least 2 dorsal horn interneurons and may thus
resemble the polysynaptic feature of circuits of hyperalgesia
rather than circuits of acute nociception.
The failure of the recent clinical trial on chronic low back pain9
cannot be ascribed to a lack of effect of a2/a3-selective GABAAR
modulators on the tonic aversive component of pain. It is unlikely
that differences in the pharmacological properties of TPA023B
and PF-6372865, which was tested the failed chronic low back
pain trial, explain the failure in the low back pain trial. Both
compounds have similar efficacies and affinities for the different
GABAAR subtypes, and both penetrate well into the CNS after
oral dosing.1,30 It is hence likely that other factors, such as a too
low dose or the selection of a patient population with merely
nociceptive rather than neuropathic pain, were responsible for
the negative outcome of the chronic low back pain trial.48
In summary, our results indicate that a facilitation of GABAergic
inhibition in the spinal dorsal horn not only reverses hyperalgesia
but also alleviates the tonic aversive component of on-going pain.
Therefore, a2/a3-selective GABAAR modulators such as
TPA023B hold promising therapeutic potential for the treatment
of the sensory as well as affective dimensions of chronic pain.
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